Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
ICT01 is an agonistic monoclonal antibody that targets BTN3A, which leads to activation of Vgamma9Vdelta2 T lymphocytes, potentially resulting in tumor cell killing, delayed tumor growth, and enhanced antitumor immune response (PMID: 34669444).
|CAS Registry Number||NA|
|Therapy Name||Drugs||Efficacy Evidence||Clinical Trials|
|Aldesleukin + ICT01||Aldesleukin ICT01||0||1|